Dermatologic Malignancy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dermatologic malignancy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dermatologic Malignancy Today - Breaking & Trending Today

Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma

1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. Grade 3-4 adverse events were more common in the nivolumab group, however, there were no reported deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Merkel cell carcinoma (MCC), an aggressive skin cancer, poses a clinical ....

Neoadjuvant Nivolumab , Eastern Cooperative Oncology Group , Rating Level , Resectable Lung , Between Oct , Dermatologic Malignancy , Merkel Cell Carcinoma , Merkel Cell Carcinoma Mcc , Skin Cancer , Chronic Disease ,